Oneness Biotech Co Ltd.

05/26/2022 | Press release | Distributed by Public on 05/26/2022 02:48

Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.

Close
Today's Information

Provided by: ONENESS BIOTECH CO., LTD.
SEQ_NO 1 Date of announcement 2022/05/26 Time of announcement 16:41:48
Subject 
 Oneness Biotech Co.,LTD receives a China patent
on antagonistic PDL1 aptamers.
Date of events 2022/05/26 To which item it meets paragraph 53
Statement 
1.Date of occurrence of the event:2022/05/26
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency that
the antagonistic PDL1 aptamer has been granted a China patent titled
"ANTAGONISTIC PDL1 APTAMERS AND THEIR APPLICATIONS IN CANCER THERAPY" under
patent number 4620171.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)This patent covers the aptamers that bind to and antagonize PDL1 and uses
   thereof in enhancing immune activity(e.g.,promoting T cell proliferation),
   treating cancer, and/or infectious diseases such as infections caused by
   enterovirus, HBV or HCV.
(2)This patent is owned by National Taiwan University and Academia Sinica.
   Oneness Biotech Co.,LTD has been exclusively authorized to use this patent
   and to manufacture, use and sell the products of this invention.